ClinicalTrials.gg
TerminatedNCT04154150Updated Jul 22, 2024Results posted

Ketamine + Cognitive Training for Suicidality in the Medical Setting: Pilot

A Phase 4 interventional study of Intravenous ketamine and Cognitive training in Suicide, Attempted, sponsored by Rebecca Price. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-22.

Sponsored by Rebecca Price · Phase 4, Interventional, and Treatment

How we know

Why this study was terminated
Midway through this pilot study, funding was obtained to support a much larger study of the same interventions in this clinical population. Therefore the pilot study was halted so as not to compete with enrollment for the larger study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 149 studies in Suicide, Attempted with a site in United States — 53 open to participants now, 58 under way, 1 of them phase 3. Suicide, Attempted · United States.

Enrollment
129th of 140
16 · median 117
Started
2019
with 7 others
Phase 4
3 of 149
none open now
Registered
57th of 149
by date

Among the 149 studies in Suicide, Attempted with a site in United States, this one is the 129th largest by enrollment of the 140 interventional ones that give a count, is one of 8 that started in 2019, is one of 3 in phase 4, and was the 57th registered.

Suicide, Attempted

281 studies on the registry are indexed under Suicide, Attempted; 90 are open to participants now.

Browse Suicide, Attempted studies →

Open to participants now

53 of the 149 studies in Suicide, Attempted with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Suicide, Attempted studies recruiting now, 34 (51%) set no upper age limit and 32 (48%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Suicide, Attempted with a site in United States, or all of them as a file.
02

Study summary

This project seeks to identify the acute and longer-term impact of a single dose of intravenous ketamine among suicidal patients referred for psychiatric consultation/liaison in the medical inpatient setting. The investigators will then test whether ketamine's rapid effects can be extended by introducing helpful information delivered by a computer-based training protocol. This work could ultimately lead to the ability to treat suicidality more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.

Read the detailed description

NOTE: In the course of this pilot study, both the primary and secondary outcome measures were supplemented to provide additional, complementary information on the clinical effects of the study interventions, based on confirmation (through study team experience) of the feasibility of acquiring such additional information in the context of our study population, setting, and design.

03

Conditions studied

  • Suicide, Attempted

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants will:

  1. be between the ages of 18 and 65 years
  2. be a medical inpatient referred for psychiatric consultation/liaison due to suicidality
  3. possess a level of judgment and understanding sufficient to agree to all procedures required by the protocol and must sign an document
  4. be deemed an appropriate and reasonable medical candidate for intravenous ketamine by a physician authorized to prescribe medication to the patient during inpatient hospitalization

Exclusion criteria

Exclusion Criteria:

  1. Presence of current psychotic or autism spectrum disorder or current delirium
  2. Use of a Monoamine Oxidase Inhibitor (MAOI) within the previous 2 weeks
  3. Current pregnancy or breastfeeding
  4. Reading level \<5th grade as per WRAT-3 reading subtest
  5. Past intolerance or to ketamine
  6. Patients taking any of the following medications: St John's Wort, theophylline, tramadol, metrizamide
  7. Patients who have received ECT in the past 6 months prior to intake
  8. Patients at risk for withdrawal related issues (e.g., delirium tremens, severe opiate withdrawal) or who present with substance-induced psychosis
  9. Patients who, based on expressed preference and/or home geographic location, are deemed by the Psychiatric Consultation/Liaison service to be likely to receive inpatient psychiatric hospitalization at an alternate location outside of Western Psychiatric Institute \& Clinic
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Ketamine + Cognitive Training

    Drug: Intravenous ketamine · Behavioral: Cognitive training

  • Sham comparator
    Ketamine + Sham Training

    Drug: Intravenous ketamine · Behavioral: Sham Training

Interventions

  • DrugKetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Single subanesthetic infusion of ketamine (0.5mg/kg)

  • BehavioralCognitive training

    8 sessions of computer-based cognitive training

  • BehavioralSham Training

    8 sessions of computer-based sham training

06

What researchers measure

Primary outcomes

  1. Montgomery Asberg Depression Rating Scale

    depression severity; range 0-60; high score=worse outcome

    Time frame: infusion +24 hours

  2. Montgomery Asberg Depression Rating Scale

    depression severity; range 0-60; high score=worse outcome

    Time frame: infusion +5 days

  3. Montgomery Asberg Depression Rating Scale

    depression severity; range 0-60; high score=worse outcome

    Time frame: infusion +12 days

  4. Montgomery Asberg Depression Rating Scale

    depression severity; range 0-60; high score=worse outcome

    Time frame: infusion +1 month

  5. Montgomery Asberg Depression Rating Scale

    depression severity; range 0-60; high score=worse outcome

    Time frame: infusion +3 months

  6. Montgomery Asberg Depression Rating Scale

    depression severity; range 0-60; high score=worse outcome

    Time frame: infusion +6 months

  7. Adult Suicide Ideation Questionnaire (Past Day Version)

    suicidal ideation/thoughts; range 0-150; high score=worse outcome

    Time frame: infusion +24 hours

  8. Adult Suicide Ideation Questionnaire (Past Day Version)

    suicidal ideation/thoughts; range 0-150; high score=worse outcome

    Time frame: infusion +5 days

  9. Adult Suicide Ideation Questionnaire (Past Day Version)

    suicidal ideation/thoughts; range 0-150; high score=worse outcome

    Time frame: infusion +12 days

  10. Adult Suicide Ideation Questionnaire

    suicidal ideation/thoughts; range 0-150; high score=worse outcome

    Time frame: infusion +1 month

  11. Adult Suicide Ideation Questionnaire

    suicidal ideation/thoughts; range 0-150; high score=worse outcome

    Time frame: infusion +3 months

  12. Adult Suicide Ideation Questionnaire

    suicidal ideation/thoughts; range 0-150; high score=worse outcome

    Time frame: infusion +6 months

Secondary outcomes

  1. Number of Participants With Occurrence of Suicidal Behaviors Per Medical Chart Review

    Number of participants with occurrence of any suicidal act (derived from medical chart) including: re-attempt, re-hospitalization for suicidality, or completed suicide

    Time frame: infusion +6 months

  2. Number of Participants Reporting Suicidal Behaviors Per the Columbia Suicide Severity Rating Scale (CSSRS)

    Number of participants with occurrence of any suicidal act (derived from Columbia Suicide Severity Rating Scale interview; each of the following items was scored yes/no for the period since last assessment: re-attempt, re-hospitalization for suicidality, or completed suicide. Analyzed outcome measure is # of participants with 1 or more 'yes' responses.

    Time frame: infusion +6 months

  3. Quick Inventory of Depressive Symptoms

    Self-reported depression (range: 0-27; higher scores = worse outcome)

    Time frame: infusion +24 hours

  4. Quick Inventory of Depressive Symptoms

    Self-reported depression (range: 0-27; higher scores = worse outcome)

    Time frame: infusion +5 days

  5. Quick Inventory of Depressive Symptoms

    Self-reported depression (range: 0-27; higher scores = worse outcome)

    Time frame: infusion +12 days

  6. Quick Inventory of Depressive Symptoms

    Self-reported depression (range: 0-27; higher scores = worse outcome)

    Time frame: infusion +1 month

  7. Quick Inventory of Depressive Symptoms

    Self-reported depression (range: 0-27; higher scores = worse outcome)

    Time frame: infusion +3 months

  8. Quick Inventory of Depressive Symptoms

    Self-reported depression (range: 0-27; higher scores = worse outcome)

    Time frame: infusion +6 months

  9. Scale for Suicide Ideation

    suicidal ideation/thoughts; range 0-38; high score=worse outcome

    Time frame: infusion +24 hours

  10. Scale for Suicide Ideation

    suicidal ideation/thoughts; range 0-38; high score=worse outcome

    Time frame: infusion +5 days

  11. Scale for Suicide Ideation

    suicidal ideation/thoughts; range 0-38; high score=worse outcome

    Time frame: infusion +12 days

  12. Scale for Suicide Ideation

    suicidal ideation/thoughts; range 0-38; high score=worse outcome

    Time frame: infusion +1 month

  13. Scale for Suicide Ideation

    suicidal ideation/thoughts; range 0-38; high score=worse outcome

    Time frame: infusion +3 months

  14. Scale for Suicide Ideation

    suicidal ideation/thoughts; range 0-38; high score=worse outcome

    Time frame: infusion +6 months

07

Results

Posted Jan 10, 2023
Limitations and caveats
Pilot study leading to small numbers of patients in each treatment arm. Descriptive statistics are reported without statistical analysis to directly compare groups, given the small number of patients within each group leading to low statistical power.

Participant flow

Participant flow — Overall Study
MilestoneKetamine + Cognitive TrainingKetamine + Sham Training
Started79
Completed79
Not completed00

Outcome measures

PrimaryMontgomery Asberg Depression Rating Scale

depression severity; range 0-60; high score=worse outcome

Time frame:
infusion +24 hours
Reported as:
Mean · score on a scale
Montgomery Asberg Depression Rating Scale
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Montgomery Asberg Depression Rating Scale18.43 ± 8.515.44 ± 10.9
PrimaryMontgomery Asberg Depression Rating Scale

depression severity; range 0-60; high score=worse outcome

Time frame:
infusion +5 days
Reported as:
Mean · score on a scale
Montgomery Asberg Depression Rating Scale
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Montgomery Asberg Depression Rating Scale19.14 ± 9.816.13 ± 9.2
PrimaryMontgomery Asberg Depression Rating Scale

depression severity; range 0-60; high score=worse outcome

Time frame:
infusion +12 days
Reported as:
Mean · score on a scale
Montgomery Asberg Depression Rating Scale
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Montgomery Asberg Depression Rating Scale13.67 ± 14.217.29 ± 11.9
PrimaryMontgomery Asberg Depression Rating Scale

depression severity; range 0-60; high score=worse outcome

Time frame:
infusion +1 month
Reported as:
Mean · score on a scale
Montgomery Asberg Depression Rating Scale
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Montgomery Asberg Depression Rating Scale20.67 ± 7.614.00 ± 13.4
PrimaryMontgomery Asberg Depression Rating Scale

depression severity; range 0-60; high score=worse outcome

Time frame:
infusion +3 months
Reported as:
Mean · score on a scale
Montgomery Asberg Depression Rating Scale
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Montgomery Asberg Depression Rating Scale13.00 ± 13.614.71 ± 10.2
PrimaryMontgomery Asberg Depression Rating Scale

depression severity; range 0-60; high score=worse outcome

Time frame:
infusion +6 months
Reported as:
Mean · score on a scale
Montgomery Asberg Depression Rating Scale
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Montgomery Asberg Depression Rating Scale13.20 ± 14.717.43 ± 9.9
PrimaryAdult Suicide Ideation Questionnaire (Past Day Version)

suicidal ideation/thoughts; range 0-150; high score=worse outcome

Time frame:
infusion +24 hours
Reported as:
Mean · score on a scale
Adult Suicide Ideation Questionnaire (Past Day Version)
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Adult Suicide Ideation Questionnaire (Past Day Version)32.67 ± 8.4541.89 ± 38.6
PrimaryAdult Suicide Ideation Questionnaire (Past Day Version)

suicidal ideation/thoughts; range 0-150; high score=worse outcome

Time frame:
infusion +5 days
Reported as:
Mean · score on a scale
Adult Suicide Ideation Questionnaire (Past Day Version)
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Adult Suicide Ideation Questionnaire (Past Day Version)20.00 ± 9.9822.88 ± 10.7
PrimaryAdult Suicide Ideation Questionnaire (Past Day Version)

suicidal ideation/thoughts; range 0-150; high score=worse outcome

Time frame:
infusion +12 days
Reported as:
Mean · score on a scale
Adult Suicide Ideation Questionnaire (Past Day Version)
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Adult Suicide Ideation Questionnaire (Past Day Version)17.17 ± 13.431.86 ± 34.6
PrimaryAdult Suicide Ideation Questionnaire

suicidal ideation/thoughts; range 0-150; high score=worse outcome

Time frame:
infusion +1 month
Reported as:
Mean · score on a scale
Adult Suicide Ideation Questionnaire
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Adult Suicide Ideation Questionnaire23.60 ± 22.941.83 ± 48.0
PrimaryAdult Suicide Ideation Questionnaire

suicidal ideation/thoughts; range 0-150; high score=worse outcome

Time frame:
infusion +3 months
Reported as:
Mean · score on a scale
Adult Suicide Ideation Questionnaire
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Adult Suicide Ideation Questionnaire25.20 ± 26.237.50 ± 46.5
PrimaryAdult Suicide Ideation Questionnaire

suicidal ideation/thoughts; range 0-150; high score=worse outcome

Time frame:
infusion +6 months
Reported as:
Mean · score on a scale
Adult Suicide Ideation Questionnaire
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Adult Suicide Ideation Questionnaire29.5 ± 40.345.75 ± 60.9
SecondaryNumber of Participants With Occurrence of Suicidal Behaviors Per Medical Chart Review

Number of participants with occurrence of any suicidal act (derived from medical chart) including: re-attempt, re-hospitalization for suicidality, or completed suicide

Time frame:
infusion +6 months
Reported as:
Count of participants · Participants
Number of Participants With Occurrence of Suicidal Behaviors Per Medical Chart Review
ParticipantsKetamine + Cognitive TrainingKetamine + Sham Training
Number of Participants With Occurrence of Suicidal Behaviors Per Medical Chart Review34
SecondaryNumber of Participants Reporting Suicidal Behaviors Per the Columbia Suicide Severity Rating Scale (CSSRS)

Number of participants with occurrence of any suicidal act (derived from Columbia Suicide Severity Rating Scale interview; each of the following items was scored yes/no for the period since last assessment: re-attempt, re-hospitalization for suicidality, or completed suicide. Analyzed outcome measure is # of participants with 1 or more 'yes' responses.

Time frame:
infusion +6 months
Reported as:
Count of participants · Participants
Number of Participants Reporting Suicidal Behaviors Per the Columbia Suicide Severity Rating Scale (CSSRS)
ParticipantsKetamine + Cognitive TrainingKetamine + Sham Training
Number of Participants Reporting Suicidal Behaviors Per the Columbia Suicide Severity Rating Scale (CSSRS)11
SecondaryQuick Inventory of Depressive Symptoms

Self-reported depression (range: 0-27; higher scores = worse outcome)

Time frame:
infusion +24 hours
Reported as:
Mean · score on a scale
Quick Inventory of Depressive Symptoms
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Quick Inventory of Depressive Symptoms12.83 ± 4.111.22 ± 6.0
SecondaryQuick Inventory of Depressive Symptoms

Self-reported depression (range: 0-27; higher scores = worse outcome)

Time frame:
infusion +5 days
Reported as:
Mean · score on a scale
Quick Inventory of Depressive Symptoms
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Quick Inventory of Depressive Symptoms9.86 ± 5.89.50 ± 6.9
SecondaryQuick Inventory of Depressive Symptoms

Self-reported depression (range: 0-27; higher scores = worse outcome)

Time frame:
infusion +12 days
Reported as:
Mean · score on a scale
Quick Inventory of Depressive Symptoms
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Quick Inventory of Depressive Symptoms8.33 ± 7.19.86 ± 7.3
SecondaryQuick Inventory of Depressive Symptoms

Self-reported depression (range: 0-27; higher scores = worse outcome)

Time frame:
infusion +1 month
Reported as:
Mean · score on a scale
Quick Inventory of Depressive Symptoms
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Quick Inventory of Depressive Symptoms9.60 ± 3.49.33 ± 7.0
SecondaryQuick Inventory of Depressive Symptoms

Self-reported depression (range: 0-27; higher scores = worse outcome)

Time frame:
infusion +3 months
Reported as:
Mean · score on a scale
Quick Inventory of Depressive Symptoms
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Quick Inventory of Depressive Symptoms10.60 ± 7.19.17 ± 7.5
SecondaryQuick Inventory of Depressive Symptoms

Self-reported depression (range: 0-27; higher scores = worse outcome)

Time frame:
infusion +6 months
Reported as:
Mean · score on a scale
Quick Inventory of Depressive Symptoms
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Quick Inventory of Depressive Symptoms10.00 ± 10.012.25 ± 10.6
SecondaryScale for Suicide Ideation

suicidal ideation/thoughts; range 0-38; high score=worse outcome

Time frame:
infusion +24 hours
Reported as:
Mean · score on a scale
Scale for Suicide Ideation
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Scale for Suicide Ideation8.50 ± 12.00.80 ± 1.3
SecondaryScale for Suicide Ideation

suicidal ideation/thoughts; range 0-38; high score=worse outcome

Time frame:
infusion +5 days
Reported as:
Mean · score on a scale
Scale for Suicide Ideation
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Scale for Suicide Ideation0.50 ± .716.60 ± 9.4
SecondaryScale for Suicide Ideation

suicidal ideation/thoughts; range 0-38; high score=worse outcome

Time frame:
infusion +12 days
Reported as:
Mean · score on a scale
Scale for Suicide Ideation
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Scale for Suicide Ideation—4.50 ± 9.0
SecondaryScale for Suicide Ideation

suicidal ideation/thoughts; range 0-38; high score=worse outcome

Time frame:
infusion +1 month
Reported as:
Mean · score on a scale
Scale for Suicide Ideation
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Scale for Suicide Ideation13.004.67 ± 7.2
SecondaryScale for Suicide Ideation

suicidal ideation/thoughts; range 0-38; high score=worse outcome

Time frame:
infusion +3 months
Reported as:
Mean · score on a scale
Scale for Suicide Ideation
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Scale for Suicide Ideation4.00 ± 7.35.83 ± 9.2
SecondaryScale for Suicide Ideation

suicidal ideation/thoughts; range 0-38; high score=worse outcome

Time frame:
infusion +6 months
Reported as:
Mean · score on a scale
Scale for Suicide Ideation
score on a scaleKetamine + Cognitive TrainingKetamine + Sham Training
Scale for Suicide Ideation5.40 ± 12.16.86 ± 9.2

Adverse events

Collected over 24 hours. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ketamine + Cognitive Training0/7 (0%)0/7 (0%)7/7 (100%)
Ketamine + Sham Training0/9 (0%)0/9 (0%)9/9 (100%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventKetamine + Cognitive TrainingKetamine + Sham Training
difficulty sleeping: too littlePsychiatric disorders3/73/9
emotional indifferencePsychiatric disorders3/72/9
nauseaGastrointestinal disorders3/70/9
anxietyPsychiatric disorders2/73/9
headacheNervous system disorders2/73/9
sweatingGeneral disorders2/73/9
constipationGastrointestinal disorders2/72/9
dizzinessNervous system disorders2/72/9
decreased energyGeneral disorders1/72/9
increased appetiteGastrointestinal disorders1/72/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ketamine + Cognitive TrainingKetamine + Sham TrainingTotal
Mean32.29 ± 14.8035.44 ± 17.7434.06 ± 16.06
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Ketamine + Cognitive TrainingKetamine + Sham TrainingTotal
Male257
Female538
Transgender (female-to-male)011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ketamine + Cognitive TrainingKetamine + Sham TrainingTotal
Hispanic or Latino134
Not Hispanic or Latino6511
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ketamine + Cognitive TrainingKetamine + Sham TrainingTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American213
White5813
More than one race000
Unknown or Not Reported000
Montgomery Asberg Depression Rating Scale
Montgomery Asberg Depression Rating Scale(units on a scale)Ketamine + Cognitive TrainingKetamine + Sham TrainingTotal
Mean39 ± 6.436.8 ± 6.337.8 ± 6.2
Adult Suicide Ideation Questionnaire
Adult Suicide Ideation Questionnaire(units on a scale)Ketamine + Cognitive TrainingKetamine + Sham TrainingTotal
Mean85.0 ± 35.296.6 ± 31.591.9 ± 32.3
Quick Inventory of Depressive Symptoms
Quick Inventory of Depressive Symptoms(units on a scale)Ketamine + Cognitive TrainingKetamine + Sham TrainingTotal
Mean17.8 ± 3.114.4 ± 5.9515.9 ± 5.1
Scale for Suicide Ideation
Scale for Suicide Ideation(units on a scale)Ketamine + Cognitive TrainingKetamine + Sham TrainingTotal
Mean30.3 ± 2.229.3 ± 1.729.6 ± 1.8
08

Study locations

1 site
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Mar 2022, 26 months.

Results were first posted in Jan 2023, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2019
First posted
Nov 6, 2019
StartActual
Dec 19, 2019
Primary completionActual
Mar 15, 2022
CompletionActual
Mar 15, 2022
Results first posted
Jan 10, 2023
Last update
Jul 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04154150
Lead sponsor
Rebecca Price
Responsible party
Rebecca Price (Associate Professor of Psychiatry and Psychology, University of Pittsburgh) — Sponsor-investigator
First posted
Nov 6, 2019
Start date
Dec 19, 2019
Primary completion
Mar 15, 2022
Completion
Mar 15, 2022
Results posted
Jan 10, 2023
Last update
Jul 22, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion